Loteprednol

Loteprednol is a medication used for treating certain eye conditions. Specifically, the lower strength (Alrex) is prescribed to treat eye allergies, and the higher strength (Lotemax) is licensed to treat various inflammatory eye conditions. The medication comes in the form of eye drops or an eye ointment and is used in the affected eye at least four times daily. Potential side effects may include blurred vision and dry eyes.

What Is Loteprednol?

Loteprednol etabonate (Alrex®, Lotemax®) is a prescription eye medication used for the treatment of a variety of different inflammatory eye conditions. It is a "steroid" eye medication.
 
The lower strength (Alrex) is approved to treat eye allergies, while the higher strength (Lotemax) is approved to treat a variety of different inflammatory eye conditions (including eye allergies) and to treat inflammation and pain that sometimes occurs after eye surgery.
 
Originally, Lotemax only came in the form of a drop. However, an eye ointment form of the medication has also been approved.
 
(Click What Is Loteprednol Used For? for more information, including possible off-label uses.)
 

Are There Side Effects?

As with any medicine, loteprednol can cause side effects.
 However, not everyone who uses the drug will experience side effects. Most people tolerate it quite well.
 
If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
 
Possible side effects of loteprednol include but are not limited to:
 
  • Abnormal or blurred vision
  • Eye burning
  • Swelling of the lining of the eye and eyelid
  • Eye discharge
  • Dry eyes.
     
(Click Side Effects of Loteprednol to learn more, including potentially serious side effects that you should report immediately to your healthcare provider.)
 
Loteprednol Article Continues on Next Page >
Written by/reviewed by: Kristi Monson, PharmD
Last reviewed by: Kristi Monson, PharmD
Other Articles in This eMedTV Presentation